The life sciences sector operates under intense pressure to bring new drugs to market faster and at lower cost, without compromising GMP compliance or quality. Bryden Wood's Design to Value approach addresses this directly: our work on the Pfizer Singapore API manufacturing facility reduced capital cost by 30% and cut operational CO₂ emissions by more than 50%. The GSK Attachment Inhibitor facility in Parma was delivered from groundbreaking to handover in 15 months – completed on budget, with no reportable safety incidents. Both projects won ISPE Facility of the Year Awards.

Most pharmaceutical projects fail not because of poor construction but because business intent is inadequately translated into design. Bryden Wood developed Design to Value specifically to solve this problem – starting every project by working with clients and stakeholders to define a precise problem statement before a single line is drawn. Our 'Chip Thinking' methodology models process requirements in 3D digital building blocks, enabling rapid optioneering across facility configurations, equipment layouts, and manufacturing strategies. This front-end investment consistently eliminates over-provision, reduces equipment count, and produces leaner, more operable facilities.

Bryden Wood's Fast Lab service applies productised design thinking to laboratory deployment – compressing the time from scientific requirement to construction-ready design from months to weeks.

Using a standardised capacity model, a configurable equipment and component library, and codified design rules, our team can run multiple design iterations with all stakeholders in a single workshop. For developers and life sciences businesses scaling rapidly, this approach removes the cost and delay of designing from scratch each time, while maintaining the flexibility to accommodate evolving science, regulation, and technology.